{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:26:00Z","timestamp":1768407960964,"version":"3.49.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA049950"],"award-info":[{"award-number":["K01DA049950"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA047347"],"award-info":[{"award-number":["R01DA047347"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K99DA057372"],"award-info":[{"award-number":["K99DA057372"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute care encounters for opioid overdose are increasingly recognized as critical opportunities to connect patients to opioid use disorder (OUD) treatment. However, national data on receipt of medication for OUD (MOUD) after overdose events are limited, particularly for new MOUD initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine MOUD receipt and timing after emergency department or inpatient encounters for opioid overdose, including patient characteristics associated with new MOUD initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective analysis of 2014\u20132019 national Medicaid claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Acute care opioid overdose events among non-dual eligible Medicaid enrollees aged 18\u201364 with continuous enrollment during the 180-day (6-month) baseline period preceding the overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>The primary outcome was any MOUD (buprenorphine, methadone, naltrexone) receipt in the 180\u00a0days after discharge. Baseline MOUD receipt was categorized by the proportion of days covered (PDC): none (reference), very low (&gt;\u20090 to\u2009&lt;\u200920%), low (20 to\u2009&lt;\u200950%), moderate (50 to\u2009&lt;\u200980%), high (\u2265\u200980%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>Of 318,536 opioid overdose events, 22.8% and 26.0% had MOUD in the 6 months before and after the event, respectively. Prior MOUD had the strongest association with follow-up MOUD, with a gradient by baseline exposure levels. In Cox models adjusting for patient sociodemographic and clinical covariates, overdose characteristics, and community-level factors, the likelihood of follow-up MOUD was 3.58 times higher for very low (95% CI\u2009=\u20093.50\u20133.66), 5.47 times higher for low (95% CI\u2009=\u20095.35\u20135.60), 7.36 times higher for moderate (95% CI\u2009=\u20097.17\u20137.56), and 16.35 times higher for high (95% CI\u2009=\u200915.92\u201316.80) baseline MOUD exposure compared to no prior MOUD. Timely follow-up MOUD within 30\u00a0days was also higher among those with (76.0%) than without (32.4%) prior MOUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Substantial gaps in MOUD receipt after opioid overdose indicate an urgent need to expand acute care interventions for treatment initiation, engagement, and referral as well as broader efforts to increase MOUD prescribing and uptake.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-10108-5","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:21:53Z","timestamp":1768339313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3705","authenticated-orcid":false,"given":"Hillary","family":"Samples","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialiang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Treitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0366-7583","authenticated-orcid":false,"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"10108_CR1","doi-asserted-by":"crossref","unstructured":"Garnett MF, Mini\u00f1o AM. Drug Overdose Deaths in the United States, 2003\u20132023. NCHS Data Brief. 2024;(522). Accessed\u00a012 Jan 2025. https:\/\/www.cdc.gov\/nchs\/products\/index.htm.","DOI":"10.15620\/cdc\/170565"},{"key":"10108_CR2","unstructured":"Centers for Disease Control and Prevention NC for HS. National Vital Statistics System, Mortality 2018\u20132023 on CDC WONDER Online Database, released in 2024. Data are from the Multiple Cause of Death Files, 2018\u20132023, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. 2024. Accessed January 13, 2025. http:\/\/wonder.cdc.gov\/mcd-icd10-expanded.html"},{"key":"10108_CR3","unstructured":"Substance Abuse and Mental Health Services Administration; Non-Fatal Overdoses. CBHSQ Short Report. Published online 2023. Accessed\u00a025 June 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39474\/Non-Fatal%20Overdoses%20Short%20Report%20Mar22%20Final.pdf"},{"key":"10108_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2018.06.004","volume":"190","author":"M Olfson","year":"2018","unstructured":"Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend. 2018;190:112-119. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.004","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10108_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamapsychiatry.2018.1471","volume":"75","author":"M Olfson","year":"2018","unstructured":"Olfson M, Crystal S, Wall M, Wang S, Liu SM, Blanco C. Causes of Death After Nonfatal Opioid Overdose. JAMA Psychiatry. 2018;75(8):820-827. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.1471","journal-title":"JAMA Psychiatry."},{"key":"10108_CR6","doi-asserted-by":"publisher","unstructured":"Warfield S, Karras E, Lilly C, Brumage M, Bossarte RM. Causes of death among U.S. Veterans with a prior nonfatal opioid overdose. Drug Alcohol Depend. 2021;219:108484. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108484","DOI":"10.1016\/j.drugalcdep.2020.108484"},{"issue":"11","key":"10108_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/jamapsychiatry.2020.1045","volume":"77","author":"M Olfson","year":"2020","unstructured":"Olfson M, Schoenbaum M, Goldman-Mellor S. Risks of Mortality Following Nonfatal Intentional and Unintentional Opioid Overdoses. JAMA Psychiatry. 2020;77(11):1191. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1045","journal-title":"JAMA Psychiatry."},{"issue":"4","key":"10108_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/jech-2019-212915","volume":"74","author":"EM Lowder","year":"2020","unstructured":"Lowder EM, Amlung J, Ray BR. Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. J Epidemiol Community Health. 2020;74(4):369-376. https:\/\/doi.org\/10.1136\/jech-2019-212915","journal-title":"J Epidemiol Community Health."},{"key":"10108_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.DRUGALCDEP.2016.02.024","volume":"162","author":"A Caudarella","year":"2016","unstructured":"Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51-55. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2016.02.024","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10108_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1080\/08897077.2016.1152342","volume":"37","author":"RM Pavarin","year":"2016","unstructured":"Pavarin RM, Berardi D, Gambini D. Emergency department presentation and mortality rate due to overdose: A retrospective cohort study on nonfatal overdoses. Subst Abus. 2016;37(4):558-563. https:\/\/doi.org\/10.1080\/08897077.2016.1152342","journal-title":"Subst Abus."},{"issue":"4","key":"10108_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s11606-020-06405-w","volume":"36","author":"J Guo","year":"2021","unstructured":"Guo J, Lo-Ciganic WH, Yang Q, et al. Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. J Gen Intern Med. 2021;36(4):908-923. https:\/\/doi.org\/10.1007\/s11606-020-06405-w","journal-title":"J Gen Intern Med."},{"key":"10108_CR12","doi-asserted-by":"publisher","unstructured":"Hawk K, D\u2019Onofrio G. Emergency department screening and interventions for substance use disorders. Addiction Science and Clinical Practice. BioMed Central Ltd. 2018;13(1). https:\/\/doi.org\/10.1186\/s13722-018-0117-1","DOI":"10.1186\/s13722-018-0117-1"},{"key":"10108_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209377","volume":"163","author":"I Danovitch","year":"2024","unstructured":"Danovitch I, Korouri S, Kaur H, et al. The addiction consultation service for hospitalized patients with substance use disorder: An integrative review of the evidence. Journal of substance use and addiction treatment. 2024;163:209377. https:\/\/doi.org\/10.1016\/j.josat.2024.209377","journal-title":"Journal of substance use and addiction treatment."},{"issue":"16","key":"10108_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. https:\/\/doi.org\/10.1001\/jama.2015.3474","journal-title":"JAMA."},{"issue":"8","key":"10108_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","volume":"174","author":"JM Liebschutz","year":"2014","unstructured":"Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369-1376. https:\/\/doi.org\/10.1001\/jamainternmed.2014.2556","journal-title":"JAMA Intern Med."},{"key":"10108_CR16","doi-asserted-by":"publisher","unstructured":"Weinstein ZM, Englander H. Reachable Moment: Hospital-Based Interventions. In: Treating Opioid Use Disorder in General Medical Settings. Springer International Publishing; 2021:43\u201356. https:\/\/doi.org\/10.1007\/978-3-030-80818-1_4","DOI":"10.1007\/978-3-030-80818-1_4"},{"issue":"3","key":"10108_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13181-019-00712-3","volume":"15","author":"PM Wax","year":"2019","unstructured":"Wax PM, Stolbach AI, Schwarz ES, Warrick BJ, Wiegand TJ, Nelson LS. ACMT Position Statement: Buprenorphine Administration in the Emergency Department. J Med Toxicol. 2019;15(3):215-216. https:\/\/doi.org\/10.1007\/s13181-019-00712-3","journal-title":"J Med Toxicol."},{"key":"10108_CR18","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ."},{"issue":"9","key":"10108_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo","year":"2021","unstructured":"Santo T, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry. 2021;78(9):979-993. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976","journal-title":"JAMA Psychiatry."},{"issue":"7","key":"10108_CR20","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction.Blackwell Publishing Ltd. 2018;113(7):1188-1209. https:\/\/doi.org\/10.1111\/add.14180","journal-title":"Addiction. Blackwell Publishing Ltd."},{"issue":"1","key":"10108_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amepre.2023.01.037","volume":"65","author":"H Samples","year":"2023","unstructured":"Samples H, Nowels MA, Williams AR, Olfson M, Crystal S. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. Am J Prev Med. 2023;65(1):19-29. https:\/\/doi.org\/10.1016\/j.amepre.2023.01.037","journal-title":"Am J Prev Med."},{"key":"10108_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209218","volume":"157","author":"AD Tipping","year":"2024","unstructured":"Tipping AD, Nowels M, Moore C, et al. Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study. Journal of Substance Use and Addiction Treatment. 2024;157:209218. https:\/\/doi.org\/10.1016\/j.josat.2023.209218","journal-title":"Journal of Substance Use and Addiction Treatment."},{"key":"10108_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2022.109269","volume":"232","author":"S Crystal","year":"2022","unstructured":"Crystal S, Nowels M, Samples H, Olfson M, Williams AR, Treitler P. Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients. Drug Alcohol Depend. 2022;232:109269. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2022.109269","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10108_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/10826084.2021.1901933","volume":"56","author":"GA Victor","year":"2021","unstructured":"Victor GA, Bailey K, Ray B. Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose. Subst Use Misuse. 2021;56(7):988-996. https:\/\/doi.org\/10.1080\/10826084.2021.1901933","journal-title":"Subst Use Misuse."},{"issue":"3","key":"10108_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018;169(3):137-145. https:\/\/doi.org\/10.7326\/M17-3107","journal-title":"Ann Intern Med."},{"issue":"5","key":"10108_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s11606-020-05645-0","volume":"35","author":"UR Essien","year":"2020","unstructured":"Essien UR, Sileanu FE, Zhao X, et al. Racial\/Ethnic Differences in the Medical Treatment of Opioid Use Disorders Within the VA Healthcare System Following Non-Fatal Opioid Overdose. J Gen Intern Med. 2020;35(5):1537-1544. https:\/\/doi.org\/10.1007\/s11606-020-05645-0","journal-title":"J Gen Intern Med."},{"issue":"1","key":"10108_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","volume":"75","author":"SM Bagley","year":"2020","unstructured":"Bagley SM, Larochelle MR, Xuan Z, et al. Characteristics of and Receipt of Medication Treatment among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. Ann Emerg Med. 2020;75(1):29-38. https:\/\/doi.org\/10.1016\/j.annemergmed.2019.07.030","journal-title":"Ann Emerg Med."},{"key":"10108_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGPO.2021.103176","volume":"93","author":"ST Allen","year":"2021","unstructured":"Allen ST, Wedlock PT, White RH, et al. Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia. International Journal of Drug Policy. 2021;93:103176. https:\/\/doi.org\/10.1016\/J.DRUGPO.2021.103176","journal-title":"International Journal of Drug Policy."},{"key":"10108_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108435","volume":"219","author":"A Macmadu","year":"2021","unstructured":"Macmadu A, Paull K, Youssef R, et al. Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study. Drug Alcohol Depend. 2021;219:108435. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108435","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10108_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/J.ANNEMERGMED.2021.10.005","volume":"79","author":"KP Chua","year":"2022","unstructured":"Chua KP, Dahlem CHY, Nguyen TD, et al. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. Ann Emerg Med. 2022;79(3):225-236. https:\/\/doi.org\/10.1016\/J.ANNEMERGMED.2021.10.005","journal-title":"Ann Emerg Med."},{"issue":"8","key":"10108_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jama.2017.7818","volume":"318","author":"W Frazier","year":"2017","unstructured":"Frazier W, Cochran G, Lo-Ciganic W, et al. Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA. 2017;318(8):750-752.","journal-title":"JAMA."},{"issue":"5","key":"10108_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5852","volume":"3","author":"AS Kilaru","year":"2020","unstructured":"Kilaru AS, Xiong A, Lowenstein M, et al. Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients. JAMA Netw Open. 2020;3(5):e205852. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5852","journal-title":"JAMA Netw Open."},{"key":"10108_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2020.107923","volume":"209","author":"RN Karmali","year":"2020","unstructured":"Karmali RN, Ray GT, Rubinstein AL, Sterling SA, Weisner CM, Campbell CI. The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose. Drug Alcohol Depend. 2020;209:107923. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2020.107923","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10108_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11606-018-4817-8","volume":"34","author":"N Koyawala","year":"2019","unstructured":"Koyawala N, Landis R, Barry CL, Stein BD, Saloner B. Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program. J Gen Intern Med. 2019;34(6):789-791. https:\/\/doi.org\/10.1007\/s11606-018-4817-8","journal-title":"J Gen Intern Med."},{"key":"10108_CR35","unstructured":"Medicaid and CHIP Payment and Access Commission (MACPAC). Medicaid and the Opioid Epidemic. Report to Congress on Medicaid and CHIP. 2017. https:\/\/www.macpac.gov\/wp-content\/uploads\/2017\/06\/Medicaid-and-the-Opioid-Epidemic.pdf"},{"key":"10108_CR36","unstructured":"Zur J, Tolbert J. The Opioid Epidemic and Medicaid\u2019s Role in Facilitating Access to Treatment. Henry J. Kaiser Family Foundation; 2018. Accessed 17 Apr 2019. http:\/\/files.kff.org\/attachment\/Issue-Brief-The-Opioid-Epidemic-and-Medicaids-Role-in-Facilitating-Access-to-Treatment"},{"key":"10108_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110963","volume":"252","author":"J Miles","year":"2023","unstructured":"Miles J, Treitler P, Hermida R, et al. Racial\/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. Drug Alcohol Depend. 2023;252:110963. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.110963","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10108_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. JAMA Netw Open. 2019;2(6):e196373. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6373","journal-title":"JAMA Netw Open."},{"issue":"4","key":"10108_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7028","volume":"5","author":"PJ Joudrey","year":"2022","unstructured":"Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V, Wang EA. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder Key Points + Supplemental content. JAMA Netw Open. 2022;5(4):227028. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7028","journal-title":"JAMA Netw Open."},{"key":"10108_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109495","volume":"236","author":"B Corry","year":"2022","unstructured":"Corry B, Underwood N, Cremer LJ, Rooks-Peck CR, Jones C. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019. Drug Alcohol Depend. 2022;236:109495. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109495","journal-title":"Drug Alcohol Depend."},{"key":"10108_CR41","doi-asserted-by":"publisher","unstructured":"Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2013;48(2 Part 1):539\u2013559. https:\/\/doi.org\/10.1111\/j.1475-6773.2012.01449.x","DOI":"10.1111\/j.1475-6773.2012.01449.x"},{"key":"10108_CR42","unstructured":"Substance Abuse and Mental Health Services Administration; Opioid Treatment Program Directory. Accessed 6 Apr 2025. https:\/\/dpt2.samhsa.gov\/treatment\/"},{"issue":"3","key":"10108_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. JAMA Netw Open. 2022;5(3):e223821. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2022.3821","journal-title":"JAMA Netw Open."},{"issue":"8","key":"10108_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27488","journal-title":"JAMA Netw Open."},{"key":"10108_CR45","doi-asserted-by":"publisher","unstructured":"Langabeer JR, Stotts AL, Cortez A, Tortolero G, Champagne-Langabeer T. Geographic proximity to buprenorphine treatment providers in the U.S. Drug Alcohol Depend. 2020;213:108131. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108131","DOI":"10.1016\/j.drugalcdep.2020.108131"},{"key":"10108_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2024.04.004","author":"ST Savitz","year":"2024","unstructured":"Savitz ST, Stevens MA, Nath B, D\u2019onofrio G, Melnick ER, Jeffery MM. Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023. Published online 2024. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.04.004","journal-title":"Published online"},{"key":"10108_CR47","doi-asserted-by":"publisher","unstructured":"Christine PJ, Larochelle MR, Lin L (Allison), McBride J, Tipirneni R. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023;4(10):e233549. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.3549","DOI":"10.1001\/jamahealthforum.2023.3549"},{"issue":"4","key":"10108_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3132","volume":"3","author":"TL Mark","year":"2020","unstructured":"Mark TL, Parish WJ, Zarkin GA. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries. JAMA Netw Open. 2020;3(4):e203132. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3132","journal-title":"JAMA Netw Open."},{"issue":"14","key":"10108_CR49","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. Subst Use Misuse. 2021;56(14):2181-2201. https:\/\/doi.org\/10.1080\/10826084.2021.1975749","journal-title":"Subst Use Misuse."},{"key":"10108_CR50","doi-asserted-by":"publisher","unstructured":"Philbin SE, Harris A, Balbale S, Bilaver L, Beestrum M, Mchugh M. Implementation of medications for opioid use disorder in U.S. emergency departments: A systematic review. Published online 2024. https:\/\/doi.org\/10.1016\/j.josat.2024.209600","DOI":"10.1016\/j.josat.2024.209600"},{"issue":"4","key":"10108_CR51","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/10826084.2023.2294964","volume":"59","author":"CH Lin","year":"2024","unstructured":"Lin CH, Siao SF, Lin PY, Shelley M, Chi YC, Lee YH. Understanding Healthcare Providers\u2019 Care for Patients with Medications Treating Opioid Use Disorder in the Emergency Department: A Scoping Review. Subst Use Misuse. 2024;59(4):622-637. https:\/\/doi.org\/10.1080\/10826084.2023.2294964","journal-title":"Subst Use Misuse."},{"key":"10108_CR52","doi-asserted-by":"publisher","unstructured":"Bozinoff N, Grennell E, Soobiah C, et al. Facilitators of and Barriers to Buprenorphine Initiation in the Emergency Department: A Scoping Review.\u00a02024;38. https:\/\/doi.org\/10.1016\/j.lana.2024.100899","DOI":"10.1016\/j.lana.2024.100899"},{"key":"10108_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108703","volume":"224","author":"PJ Roy","year":"2021","unstructured":"Roy PJ, Price R, Choi S, et al. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021;224:108703. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108703","journal-title":"Drug Alcohol Depend."},{"key":"10108_CR54","doi-asserted-by":"publisher","unstructured":"Chhabra N, Smith D, Dickinson G, et al. Trends and Disparities in Initiation of Buprenorphine in US Emergency Departments, 2013\u20132022. JAMA Netw Open. 2024;(9). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35603","DOI":"10.1001\/jamanetworkopen.2024.35603"},{"key":"10108_CR55","unstructured":"U.S. Drug Enforcement Administration Office of Diversion Control, Title 21, Code of Federal Regulations 1306.07. Administering or dispensing of narcotic drugs. https:\/\/www.deadiversion.usdoj.gov\/21cfr\/cfr\/1306\/1306_07.htm\u00a0"},{"key":"10108_CR56","doi-asserted-by":"publisher","unstructured":"D\u2019Onofrio G, Herring AA, Perrone J, et al. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024;7(7). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.20702","DOI":"10.1001\/jamanetworkopen.2024.20702"},{"key":"10108_CR57","doi-asserted-by":"publisher","unstructured":"Goedel WC, Shapiro A, Cerd\u00e1 M, Tsai JW, Hadland SE, L Marshall BD. Association of Racial\/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Netw Open. 2020;3(4):203711. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3711","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"10108_CR58","doi-asserted-by":"publisher","unstructured":"Degenhardt L, Clark MClinNeuro B, Macpherson MPH G, et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 2023;10:386\u2013402. https:\/\/doi.org\/10.1016\/S2215-0366(23)00095-0","DOI":"10.1016\/S2215-0366(23)00095-0"},{"issue":"3","key":"10108_CR59","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/add.15233","volume":"116","author":"D Furr-Holden","year":"2021","unstructured":"Furr\u2010Holden D, Milam AJ, Wang L, Sadler R. African Americans now outpace whites in opioid\u2010involved overdose deaths: a comparison of temporal trends from 1999 to 2018. Addiction. 2021;116(3):677-683. https:\/\/doi.org\/10.1111\/add.15233","journal-title":"Addiction."},{"issue":"6","key":"10108_CR60","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","volume":"40","author":"B Andraka-Christou","year":"2021","unstructured":"Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff. 2021;40(6):920-927. https:\/\/doi.org\/10.1377\/hlthaff.2020.02261","journal-title":"Health Aff."},{"key":"10108_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk Factors for Discontinuation of Buprenorphine Treatment for Opioid Use Disorders in a Multi-State Sample of Medicaid Enrollees. J Subst Abuse Treat. 2018;95:9-17. https:\/\/doi.org\/10.1016\/j.jsat.2018.09.001","journal-title":"J Subst Abuse Treat."},{"key":"10108_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112389","volume":"263","author":"AR Williams","year":"2024","unstructured":"Williams AR, Mauro CM, Chiodo L, et al. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug Alcohol Depend. 2024;263:112389. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112389","journal-title":"Drug Alcohol Depend."},{"key":"10108_CR63","doi-asserted-by":"publisher","unstructured":"Hedegaard H, Mini\u00f1o AM, Spencer MR, Warner M. Drug Overdose Deaths in the United States, 1999\u20132020. 2021. https:\/\/doi.org\/10.15620\/cdc:112340","DOI":"10.15620\/cdc:112340"},{"key":"10108_CR64","doi-asserted-by":"crossref","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug Overdose Deaths in the United States, 2001\u20132021. NCHS Data Brief. 2022;457. Accessed 14 Feb 2023. https:\/\/www.cdc.gov\/nchs\/products\/index.htm.","DOI":"10.15620\/cdc:122556"},{"issue":"12","key":"10108_CR65","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/add.16652","volume":"119","author":"RK Ross","year":"2024","unstructured":"Ross RK, Rudolph KE, Shover CL. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018\u20132022. Addiction. 2024;119(12):2211-2215. https:\/\/doi.org\/10.1111\/add.16652","journal-title":"Addiction."},{"key":"10108_CR66","doi-asserted-by":"publisher","unstructured":"Stopka TJ, Dalvi N, Young LD, Shrestha S, Valerio DD, Walley AY. Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing. JAMA Netw Open. 2025;8(4). https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.3158","DOI":"10.1001\/jamanetworkopen.2025.3158"},{"key":"10108_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001457","author":"GP Guy","year":"2025","unstructured":"Guy GP, Jones CM, Rikard M, Strahan AE, Zhang K, Olsen Y. Individuals Dispensed Buprenorphine in the United States before and after Federal Policy Changes Aimed at Increasing Access. J Addict Med. Published online 2025. https:\/\/doi.org\/10.1097\/ADM.0000000000001457","journal-title":"J Addict Med. Published online"},{"issue":"1","key":"10108_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amepre.2024.09.013","volume":"68","author":"MM Ali","year":"2025","unstructured":"Ali MM, Chen J, Novak PJ. Utilization of Buprenorphine for Opioid Use Disorder After the Practitioner Waiver Removal. Am J Prev Med. 2025;68(1):207-209. https:\/\/doi.org\/10.1016\/j.amepre.2024.09.013","journal-title":"Am J Prev Med."},{"key":"10108_CR69","doi-asserted-by":"publisher","unstructured":"Golden AG, Piper BJ. Dynamic changes in methadone distribution for opioid use disorder treatment from 2019 to 2023. medRxiv. Published online November 10, 2024. https:\/\/doi.org\/10.1101\/2024.11.10.24317059","DOI":"10.1101\/2024.11.10.24317059"},{"issue":"9","key":"10108_CR70","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1377\/hlthaff.2025.00343","volume":"44","author":"S Crystal","year":"2025","unstructured":"Crystal S, Xie F, Samples H, et al. States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018\u201324. Health Aff. 2025;44(9):1102-1111. https:\/\/doi.org\/10.1377\/hlthaff.2025.00343","journal-title":"Health Aff."},{"issue":"5","key":"10108_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8469","volume":"8","author":"J Constantin","year":"2025","unstructured":"Constantin J, Kenney GM, Simon K, Chua KP. Medicaid Unwinding and Changes in Buprenorphine Dispensing. JAMA Netw Open. 2025;8(5):258469. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8469","journal-title":"JAMA Netw Open."},{"issue":"3","key":"10108_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14429","volume":"60","author":"H Samples","year":"2025","unstructured":"Samples H, Lloyd K, Ryali R, et al. Completeness and quality of comprehensive managed care data compared with fee\u2010for\u2010service data in national Medicaid claims from 2001 to 2019. Health Serv Res. 2025;60(3):e14429. https:\/\/doi.org\/10.1111\/1475-6773.14429","journal-title":"Health Serv Res."},{"key":"10108_CR73","doi-asserted-by":"publisher","unstructured":"Chughtai MA, Kim JY, Donohue JM, Huskamp HA, Mehrotra A, Barnett ML. Benchmarking the Transformed Medicaid Statistical Information System Analytic Files for analysis of opioid use disorder treatment. Health Serv Res. Published online December 29, 2024:e14422. https:\/\/doi.org\/10.1111\/1475-6773.14422","DOI":"10.1111\/1475-6773.14422"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10108-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:02:08Z","timestamp":1768384928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10108-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":73,"alternative-id":["10108"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10108-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was determined exempt by the Rutgers University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Dr. Samples has received consulting fees from The Pew Charitable Trusts outside this work. All other authors have no potential conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}